Statistics for SKYSCRAPER-02: Primary Results of A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide (CE) with or Without Tiragolumab (tira) in Patients (pts) With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Total visits

views
SKYSCRAPER-02: Primary Results of A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide (CE) with or Without Tiragolumab (tira) in Patients (pts) With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). 1

Total visits per month

views
September 2025 0
October 2025 0
November 2025 0
December 2025 0
January 2026 0
February 2026 1
March 2026 0